Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2022-04-27 Share Issue/Capital Cha…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics announces successful capital raising with a gross sum of approximately EUR 15.6 M EUR
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing that Quantum Genomics has successfully completed a capital raising operation, securing approximately €15.6 M through the issuance of new shares, partly to a strategic partner (Julphar). Key phrases like "successful capital raising," "new financial means," "subscription of capital increase," and details about share issuance price and shareholder structure changes clearly indicate a financing event. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific corporate finance action.
2022-04-27 English
Quantum Genomics annonce le succès de sa levée de fonds pour un montant brut d'environ 15,6 M EUR
Share Issue/Capital Change Classification · 99% confidence The document is a press release titled "Quantum Genomics annonce le succès de sa levée de fonds pour un montant brut d'environ 15,6 M€" (Quantum Genomics announces the success of its fundraising for a gross amount of approximately €15.6 million). The text details the issuance of new shares, the price, the total amount raised, and the participation of specific investors (like Julphar and Otium Capital), including changes in shareholding percentages. This content directly relates to the company raising capital and changing its capital structure. This aligns perfectly with the definition for Capital/Financing Update (Code: CAP). It is not an Earnings Release (ER) as it focuses on financing, nor is it a general Regulatory Filing (RNS) because a more specific category exists.
2022-04-27 French
Quantum Genomics Raises a Gross Amount of Approximately EUR 15 M
Capital/Financing Update Classification · 98% confidence The document is titled "Quantum Genomics Raises a Gross Amount of Approximately € 15 M" and details the launch of a capital increase, subscription commitments from institutional investors (Otium Capital, Vatel Capital), and a simultaneous reserved capital increase involving Julphar. This content directly relates to fundraising, financing activities, and changes in capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions the 'Annual General Meeting' in passing regarding a prior resolution, the primary subject is the current capital raise, not the AGM materials or voting results.
2022-04-26 English
Quantum Genomics annonce une levée de fonds pour un montant brut d'environ 15 M EUR
Capital/Financing Update Classification · 99% confidence The document is titled "Quantum Genomics annonce une levée de fonds pour un montant brut d'environ 15 M€" (Quantum Genomics announces a fundraising for a gross amount of approximately €15 M). The text details the launch of a capital increase ('augmentation de capital') with the exclusion of pre-emptive subscription rights, involving institutional investors and a concurrent capital increase reserved for Julphar. This clearly describes a financing activity aimed at raising capital for business objectives (finalizing firibastat launch, exploring new therapeutic areas). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). The document is a formal announcement detailing the structure and purpose of the fundraising, not just a brief notice of a report.
2022-04-26 French
Quantum Genomics annonce la publication d'un nouvel article scientifique sur son produit QGC606
Regulatory Filings Classification · 94% confidence The document is a press release titled "Quantum Genomics annonce la publication d'un nouvel article scientifique sur son produit QGC606" (Quantum Genomics announces the publication of a new scientific article on its product QGC606). It details the findings of a scientific paper published in the *Canadian Journal of Cardiology* regarding their drug candidate QGC606. This is not a formal regulatory filing like a 10-K, IR, or ER. It is an announcement about scientific progress and publication. Since there is no specific category for 'Scientific Publication Announcement', and it is a general corporate update announcing external information availability, it best fits the general regulatory/corporate announcement category, which is RNS (Regulatory Filings) as a fallback, or potentially IP (Investor Presentation) if it were a presentation, but here it is a publication announcement. Given the options, RNS is the most appropriate catch-all for significant, non-standard corporate news releases that aren't explicitly covered by other codes (like ER, CT, or DIV). However, since it is announcing the publication of research, it is a form of corporate information dissemination. Given the strict definitions, and the fact that it is an announcement about a publication, RNS is the best fit among the provided codes for a general corporate update that isn't a financial report or management change.
2022-03-31 French
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
Report Publication Announcement Classification · 98% confidence The document is a press release titled "Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606." It details the publication of research findings in the *Canadian Journal of Cardiology* regarding their drug candidate QGC606. The text is short (3642 characters) and its primary function is to announce that a report (the scientific article) has been published and provide a link to it. According to Rule #2 (The 'MENU VS MEAL' Rule), when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA). It is not the full scientific article itself, nor is it a standard regulatory filing like 10-K or ER.
2022-03-31 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.